AzTrials
AzTrials

Vitamin A DeficiencyNCT03305042

Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death

An observational study of Vitamin A Deficiency and Vitamin A Toxicity, run by University of Wisconsin, Madison at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Minimal human data exist on actual liver vitamin A compared with blood biomarkers. One blood biomarker, the percent of total serum retinol (vitamin A) in the form of retinyl esters, has been suggested to diagnose hypervitaminosis A with cutoffs of 5% and 10%. Read more about this study

Who is it for?
Ages 21 years and olderHealthy volunteers can take part
Conditions the study is for
Vitamin A Deficiency, Vitamin A Toxicity
How many people
27 participants
Where
1 siteUnited States
Study dates
1 Feb 2012to 31 Jan 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: US adult cadavers from the the National Disease Research Interchange service age 21 years and older, death from any cause.

Who may be able to join

  • Human liver and serum samples were acquired as a consecutive sample through a request to the National Disease Research Interchange service, based on sex and age range targets (5 male and 5 female per age group; age groups: 21-54 ; 55-74; 75 and above).

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Wisconsin - Madison

    Madison, Wisconsin, 53706

Other trials in United States

About this study

Minimal human data exist on actual liver vitamin A compared with blood biomarkers. One blood biomarker, the percent of total serum retinol (vitamin A) in the form of retinyl esters, has been suggested to diagnose hypervitaminosis A with cutoffs of 5% and 10%. In this study, investigators aim to compare total liver vitamin A reserves with the percent total serum retinol as retinyl esters to evaluate hypervitaminosis A using autopsy samples from US adults. Investigators also evaluate the sensitivity (the ability of the biomarker to correctly identify those with deficiency) and specificity (the ability of the biomarker to correctly identify those without deficiency) of serum retinol to determine vitamin A deficiency, variation of liver vitamin A concentration among lobes, and liver alpha retinyl ester concentrations, a cleavage product of alpha-carotene, a vitamin A precursor. To conduct the study, matched serum and liver samples were procured from 27 US adult cadavers (from donors age 49-101 years) and their vitamin A biomarkers were analyzed.

Read the detailed description

Minimal human data exist on actual liver vitamin A compared with blood biomarkers. One blood biomarker, the percent of total serum retinol (vitamin A) in the form of retinyl esters, has been suggested to diagnose hypervitaminosis A with cutoffs of 5% and 10%. In this study, investigators aim to compare total liver vitamin A reserves with the percent total serum retinol as retinyl esters to evaluate hypervitaminosis A using autopsy samples from US adults. Investigators also evaluate the sensitivity (the ability of the biomarker to correctly identify those with deficiency) and specificity (the ability of the biomarker to correctly identify those without deficiency) of serum retinol to determine vitamin A deficiency, variation of liver vitamin A concentration among lobes, and liver alpha retinyl ester concentrations, a cleavage product of alpha-carotene, a vitamin A precursor.

To conduct the study, matched serum and liver samples were procured from 27 US adult cadavers (from donors age 49-101 years) and their vitamin A biomarkers were analyzed. Matched human liver and serum samples were collected from 27 cadavers, 13 male and 14 female, and acquired as a consecutive sample through a request to the National Disease Research Interchange service. De-identified clinical history summaries were also obtained. The donor criteria were as follows: no restrictions on race or sex, no history of chemotherapy and/or radiation, no history of prolonged endotracheal intubation or ventilation, no evidence of sepsis or infectious disease (negative serology panel), and age ranges of 21-54 y, 55-74 y, and >75 y (target collection was 5 male and 5 female donors per age range to provide a non-homogenous sample). After 10 individuals were acquired in each age range (i.e., 55-74 y and >75 y), samples were no longer requested. All tissues and sera were procured within 16 h post-mortem from September 2013 through August 2016. The procurement protocol numbers were DWEN1 002 022, 002 023, and 002 024 for frozen liver, embedded liver, and serum, respectively. Serum samples were isolated via gel separation and then frozen; primary liver samples were snap frozen in liquid N2; a second liver sample from each donor was embedded in optimal cutting temperature compound (OCT) and snap frozen in a cryomold. Two livers were procured almost whole and evaluated for VA distribution within and among lobes. Samples were shipped on dry ice to Madison, WI, and stored in a -80°C freezer.

OCT-embedded liver samples were prepared as 5-µm frozen sections using a cryostat and stained using routine hematoxylin and eosin and Masson's trichrome protocols and reagents (Newcomer Supply, Middleton, WI). Images were captured using a Nikon E-600 bright field microscope (Melville, NY) and Olympus DP-71 digital microscopy camera (Center Valley, PA). Liver samples (1 g) for VA and carotenoid analyses were weighed and then ground with sodium sulfate (4-5 g) in a mortar and pestle using published methods with minor modifications. Purified C-23 beta-apo-carotenol was added to determine extraction efficiencies. Samples were extracted repeatedly with dichloromethane and filtered through WhatmanTM #1 (GE Healthcare Life Sciences, Pittsburgh, PA) into 50-mL volumetric flasks. An aliquot (5 mL) was dried under nitrogen, re-dissolved in 300 µL methanol:dichloroethane (75:25, volume:volume) and an aliquot of 1 µL was injected into a Waters Acquity H-Class ultra-pressure liquid chromatograph (UPLC®) system equipped with a photodiode array detector (Milford, MA). Aliquots were further saponified for quantification of total alpha-retinol as described below for the lobe analyses. For the liver lobe sample evaluations, 1 g samples were extracted in triplicate from each available lobe. A 5-mL aliquot of the extract was saponified with 400 mL potassium hydroxide:water (50:50, weight:volume) at 45°C for 1 h. The reaction was quenched with 0.5 mL water and extracted three times with 0.5 mL hexanes. The hexane layers were pooled and dried under nitrogen, redissolved in 150 µL methanol:dichloroethane (75:25, volume:volume), and an aliquot of 1 µL was injected into the UPLC® system.

Serum samples (0.5 mL) were aliquoted into test tubes for retinol and RE determination; 1.25 X volume of ethanol was added to denature proteins. The internal standard was C23-β-apo-carotenol. Samples were extracted three times with 0.75 mL hexanes; the supernatant fractions were pooled and dried under nitrogen and reconstituted in 100 µL methanol: dichloroethane (75:25, volume:volume). Two µL was injected into the UPLC® under the conditions described below. Serum C-reactive protein (CRP) and alpha1-acid glycoprotein (AGP) were analyzed to evaluate inflammation using ELISA kits (CRP: Cayman Chemical Company; AGP: Abcam). Lycopene and alpha- and beta-carotene concentrations were determined by routine HPLC analysis.

Ultra-high Performance Liquid Chromatograph (UPLC) method A Waters Acquity UPLC HSS C18 1.8 µm VanGuard pre-column was used in conjunction with a Waters Acquity UPLC® HSS C18 column (1.8 µm, 2.1 x 150 mm). The method utilized two solvent mixes programmed for a 29-min gradient. Solvent A was acetonitrile-water-isopropanol (70:25:5, volume:volume:volume) with 10 mmol/L ammonium acetate and solvent B was methanol-isopropanol (75:25, volume:volume). The column temperature was set to 32°C and flow rate was 0.4 mL/min. The gradient began by holding 100% solvent A for 7 min, followed by a 4-min linear transition to 5% A, and another transition to 1% A over 12 min. The solvent gradient was then reversed to 100% A in 2 min and equilibrated for 4 min. Chromatograms were generated at 311 nm for α-retinol and α-REs, 325 nm for retinol and REs, and 450 nm for carotenoids. alpha-REs, derived almost exclusively from beta-carotene in the diet, were quantified as a proxy for long-term vegetable exposure. The concentrations were calculated using standard curves derived from authentic HPLC-purified standards of α-retinol and retinol.

Keywords
aging, alpha-retinol, hypervitaminosis A, vitamin A biomarkers, serum retinol
Medical subject headings
Vitamin A Deficiency, Hypervitaminosis A

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03305042
Study groupRoleWhat they receive
21-54 yAges 21-54 y
55-74 yAges 55-74 y
>75 yAge >75 y

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Serum retinyl esters, nmol/L

    Concentration of retinyl esters in subjects' serum

    Measured: Enrollment

  2. Liver vitamin A reserves, µmol/g

    Concentration of vitamin A in subjects' liver samples

    Measured: Enrollment

Secondary outcomes (2)
  1. Serum retinol, µmol/L

    Concentration of retinol in subjects' serum

    Measured: Enrollment

  2. Liver alpha-retinyl ester, nmol/g

    Concentration of alpha-retinyl esters in subjects' liver samples

    Measured: Enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2017
  2. Study start1 Feb 2012
  3. Primary completion31 Jan 2017
  4. Study completion31 Jan 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03305042
Sponsor's protocol ID
2015-1482
Status last verified
Oct 2017
First submitted
29 Sep 2017
Last updated
17 Oct 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Olsen K, Suri DJ, Davis C, Sheftel J, Nishimoto K, Yamaoka Y, Toya Y, Welham NV, Tanumihardjo SA. Serum retinyl esters are positively correlated with analyzed total liver vitamin A reserves collected from US adults at time of death. Am J Clin Nutr. 2018 Nov 1;108(5):997-1005. doi: 10.1093/ajcn/nqy190.

    PubMed 30475970

Questions about this trial

What is this clinical trial studying?

An observational study of Vitamin A Deficiency and Vitamin A Toxicity, run by University of Wisconsin, Madison at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Serum retinyl esters, nmol/L (time frame: Enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03305042, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2017; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in